The Truth About Where Your Peptides Actually Come From

Peptides are built through something called solid phase peptide synthesis, which is a process where individual amino acids are attached to a solid resin bead one at a time, in sequence, until the full chain is assembled. Each amino acid gets chemically protected before it is added, then the protecting group is removed, then the next amino acid is added, and this cycle repeats for every single position in the chain. After the chain is complete, the peptide gets cleaved off the resin and pushed through something called HPLC, which stands for high-performance liquid chromatography and is a purification method that separates the target peptide from synthesis byproducts based on how each molecule interacts with a liquid solvent moving through a packed column.

Understanding this process matters because it immediately explains why peptides are not like other compounds that circulate in gray markets. Testosterone and other anabolic steroids can be brewed from raw powder using relatively simple equipment, and this has been happening in home labs for decades. Peptide synthesis requires equipment that costs hundreds of thousands of dollars, sterile conditions, and chemists who understand the chemistry well enough to troubleshoot a synthesis that goes wrong. The barrier to entry is not higher regulations but higher physics and chemistry, and no amount of motivation or black market entrepreneurialism changes that.

Why Raw Materials Tell a Different Story Than Manufacturing Location

Even once you accept that peptides require serious infrastructure to produce, there is still a layer of the supply chain that most people never think about. Peptide synthesis does not start from nothing. It starts from something called protected amino acids, which are amino acid building blocks that have been chemically modified so they do not react in unwanted ways during the synthesis cycle. These building blocks, along with the resins the chains grow on and the coupling reagents that bond each amino acid to the next, all have to come from somewhere before synthesis even begins.

China produces approximately 80 percent of the global generic API supply, where API stands for active pharmaceutical ingredient, meaning the chemically active compound in a drug or research compound. This means that every facility on earth that synthesizes peptides, regardless of its country of final manufacture, is drawing its raw materials from Chinese chemical supply chains. A peptide synthesized in Colorado using Chinese protected amino acids is still chemically dependent on Chinese manufacturing upstream, so the origin story is never as clean as a company's marketing implies.

The Five Facilities and Why None of Them Are Selling to Research Websites

There are roughly five facilities in the United States that manufacture peptides at meaningful scale. Cordon Pharma operates out of Boulder, Colorado with several hundred employees and substantial reactor capacity. AmbioFarm runs facilities in both South Carolina and Shanghai. CPC Scientific is primarily based in Hangzhou, China and is developing a California facility that was not projected to be operational until 2026. SK Pharm-Teco in California was similarly coming online around the same timeline. Companies like BayCam and Cambrex handle pharmaceutical API production on the larger end of the market.

These facilities exist inside pharmaceutical supply chains, not gray market ones. They produce peptides for FDA-approved drugs, for clinical trials, and for compounding pharmacy distributors that operate under their own regulatory oversight. Their production schedules are locked in months in advance through multimillion dollar contracts with pharmaceutical clients. The economics of USGMP production, where USGMP refers to manufacturing that follows United States Good Manufacturing Practice guidelines set by the FDA, produce costs that run hundreds to thousands of dollars per gram of finished peptide. A research website selling a 10 milligram vial for fifty dollars and still generating profit cannot be sourcing from these facilities because the math does not work and the supply does not exist.

What "Made in the USA" Actually Means in This Market

When a research peptide company says their product is made in the USA, there are a small number of things this phrase can actually mean in practice. The most straightforward possibility is that the claim is simply false and the company is relabeling Chinese product. A second possibility is that a US address receives bulk peptide synthesized in China, divides it into individual vials, and ships it out, which means final packaging happened domestically but synthesis did not. A third possibility involves sourcing from a company like AmbioFarm, which operates facilities in two countries, meaning the peptide could have come from either location with no reliable way for the buyer to know which one. A fourth version is that a company receives Chinese bulk peptide, sends a sample to a US laboratory for purity testing, and then markets the resulting document as evidence of US quality control while calling the product US-made.

Chinese manufacturers openly offer something called OEM and ODM services, where OEM stands for original equipment manufacturer and ODM stands for original design manufacturer, and these terms in this context mean that a company can purchase bulk peptide from a Chinese supplier and receive it with custom branding already applied or applied after the fact. These services are listed publicly on platforms like Alibaba and MadeInChina.com, with catalogs of over 190 peptides available for private labeling and some suppliers requiring no minimum order quantity.

What a COA Is and How It Became a Marketing Tool

A COA, which stands for certificate of analysis, is a document produced by a laboratory that records the results of testing performed on a specific sample of a compound. A COA for a peptide will typically include the peptide name, a batch number, the date testing was performed, the method used (almost always HPLC), a purity percentage showing how much of the sample is the target peptide versus synthesis byproducts or other impurities, and sometimes additional data from mass spectrometry, which is an analytical technique that confirms molecular weight and can help verify that the peptide has the correct structure.

COAs originated as business-to-business verification tools, meaning a research company would send a sample from a new supplier to a testing laboratory to confirm the supplier was delivering what they claimed before committing to a larger purchase. This is a reasonable quality control step for any business buying bulk raw material. At some point, companies began making these documents visible to retail customers as a way to signal transparency and differentiate themselves in a crowded market, and because it worked as marketing, every company in the space eventually adopted it as a baseline expectation or faced looking suspicious by comparison.

The logic problem that nobody addresses openly is that these compounds are sold as research chemicals, legally designated for laboratory research use only. Actual research laboratories have analytical equipment on site and trained personnel who can verify purity independently. A working researcher does not need a supplier's COA because they have the means to generate their own data. The demand from consumers for public COAs is therefore an open acknowledgment that the people buying these compounds are not using them in laboratory research contexts, and everyone involved in the industry understands this, but saying it plainly would create its own legal exposure.

The Transparency Trap

There is a structural tension in this market that creates a self-defeating dynamic. Consumers, often influenced by content that emphasizes fear around contamination and heavy metals and underdosing, demand visible proof of quality in the form of public COAs. Companies respond by posting COA documents online to compete and retain customers. But when a batch gets submitted to a third-party laboratory and those results are published on a website, those results are not only visible to consumers. They are visible to regulators, to law enforcement, and to pharmaceutical companies that have legal and financial reasons to push for enforcement against gray market competitors.

Companies like Eli Lilly and Novo Nordisk have billions of dollars invested in peptide-based drugs and have financial motivation to lobby for FDA enforcement against unregulated competitors selling similar compounds at a fraction of the price. Every publicly posted COA represents a documented batch of a specific compound being sold for human use under the cover of research designation, and that documentation creates exactly the kind of paper trail that supports enforcement action. The small research chemical companies feel they cannot compete without posting COAs, so they do it, and in doing so they collectively generate the evidence that makes regulatory pressure more actionable.

The Structural Contradiction at the Center of Consumer Expectations

The underlying tension in all of this is that research chemical pricing exists because research chemicals do not go through the regulatory process that pharmaceutical drugs do. The costs that pharmaceutical companies pass on to consumers through prescription pricing reflect FDA review processes, clinical trial requirements, manufacturing inspections, and liability frameworks, and these costs are real and substantial. Compounding pharmacies that produce peptides legally operate under their own regulatory structure with their own compliance costs. The gray market price exists specifically because those costs are absent.

Demanding pharmaceutical-grade certainty at gray market prices requires that a company somehow absorb the costs of high-confidence manufacturing and third-party verification while still pricing below the legitimate market, and that is not a business model that can exist for long. A consumer who wants guaranteed purity, verified country of origin, medical oversight, and documented manufacturing standards has a clear pathway through licensed clinics and compounding pharmacies, and that pathway has a corresponding price. A consumer who participates in the gray market is trading those guarantees for lower cost and accepting the uncertainty that comes with operating outside regulated channels.

The more consumers drag gray market companies into public visibility through demands for documentation and transparency, the faster the conditions that allow gray markets to function disappear, and the only beneficiaries of that outcome are the pharmaceutical companies charging prices that most people cannot sustain long term.

---

References

1. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods. 2020. Source
2. Lindsey WT, Olin BR. PubMed searches: overview and strategies for clinicians. Nutr Clin Pract. 2013. Source
3. Pirani C, Camilleri J. Effectiveness of root canal filling materials and techniques for treatment of apical periodontitis: A systematic review. Int Endod J. 2023. Source
4. Boysen RI, Hearn MT. Purification of Peptides from Solid-Phase Peptide Synthesis with RP-HPLC. CSH Protoc. 2006. Source
5. Dirin M, Urban E, Noe CR et al.. Fragment-based solid-phase assembly of oligonucleotide conjugates with peptide and polyethylene glycol ligands. Eur J Med Chem. 2016. Source
6. Mende F, Beisswenger M, Seitz O. Automated Fmoc-based solid-phase synthesis of peptide thioesters with self-purification effect and application in the construction of immobilized SH3 domains. J Am Chem Soc. 2010. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness